Business · 05/10/2017Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for TECFIDERA Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of TECFIDERA, a human drug product, following a submission to the US Patent and Trademark Office (USPTO).
Original source language: Federal Register — Food and Drug AdministrationOpen original release →